Skip to main content

Advertisement

SpringerLink
Log in

Hormonal therapy for postmenopausal breast cancer: the science of sequencing

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Oestrogens play important roles in the natural history of breast cancer. Consequently, therapies have been developed to reduce oestrogen levels or to block signalling through oestrogen receptors (ER). These therapies include tamoxifen, selective oestrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective oestrogen receptor downregulators (SERDs). All have proven clinical efficacy in postmenopausal women with ER-positive breast cancer and can be effective in the neoadjuvant and adjuvant settings, and in the management of advanced disease. This range of endocrine therapies offers the opportunity for prolonging benefit from treatment and delaying tumour recurrence/progression by combining the different classes of drugs or by using them sequentially. Evaluation of the potential clinical benefits of concomitant or sequential endocrine therapies should be based on considerations of efficacy and safety profiles, mechanisms of action/resistance and effects on tumour biology. Evidence from preclinical models and from randomized clinical trials in patients with postmenopausal breast cancer suggests that concomitant endocrine therapies are no more effective than AIs alone. However, using AIs either as initial therapy or sequentially after tamoxifen appears to produce more benefits beyond the use of tamoxifen alone.

Currently, there are no proven algorithms for the planned, sequential use of the full range of endocrine therapies, particularly for the majority of patients who present with early breast cancer. Prospective, randomized clinical trials are needed to determine the best use of therapies in particular settings, taking into account the spectrum of molecular phenotypes in different tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90:153–159

    Article  PubMed  CAS  Google Scholar 

  2. Travis RC, Key TJ (2003) Oestrogen exposure and breast cancer risk. Breast Cancer Res 5:239–247

    Article  PubMed  CAS  Google Scholar 

  3. Liehr JG (2001) Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 7:273–281

    Article  PubMed  CAS  Google Scholar 

  4. Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis—some new perspectives. Endocrinology 142:4589–4594

    Article  PubMed  CAS  Google Scholar 

  5. Miller WR (2004) Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 18:1–32

    Article  PubMed  CAS  Google Scholar 

  6. Mouridsen HT, Rose C, Brodie AH, Smith IE (2003) Challenges in the endocrine management of breast cancer. Breast 12(Suppl 2):S2–S19

    Article  PubMed  Google Scholar 

  7. Gradishar WJ (1998) Tamoxifen—what next? Oncologist 9:378–384

    Article  Google Scholar 

  8. Peto R (1998) Mortality from breast cancer in UK has decreased suddenly. BMJ 317:476–477

    PubMed  CAS  Google Scholar 

  9. Peto R (2002) Update of the worldwide evidence on the adjuvant treatement of breast cancer. Eur J Cancer 38:E11

    Google Scholar 

  10. Bentrem D, Gaiha P, Jordan V (2003) Oestrogens, oestrogen receptors and breast cancer. Eur J Cancer (Suppl 1):1–12

  11. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238

    Article  PubMed  CAS  Google Scholar 

  12. Vergote I, Robertson JF (2004) Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 90(Suppl 1):S11–S14

    Article  PubMed  CAS  Google Scholar 

  13. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101–112

    Article  PubMed  Google Scholar 

  14. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) ATAC trialists‘ group: anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  PubMed  CAS  Google Scholar 

  15. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461

    PubMed  CAS  Google Scholar 

  16. Nabholtz J, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a north American multicenter randomized trial. J Clin Oncol 18:3758–3767

    PubMed  CAS  Google Scholar 

  17. Kaufmann M, Bajetta E, Dirix L, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18:1399–1411

    PubMed  CAS  Google Scholar 

  18. Bonneterre J, Buzdar A, Nabholtz J, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Arimidex writing committee; investigators committee members: anastrozole is superior to taxomifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258

    Article  PubMed  CAS  Google Scholar 

  19. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 19:2596–2606

    PubMed  CAS  Google Scholar 

  20. Paridaens R, Therasse P, Dirix L, Beex L, Piccart MJ, Cameron D, Cufer T, Roozendael K, Nooy M, Mattiacci MR (2004) First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC)—EORTC 10951 in collaboration with the exemestane working group and NCIC. Eur J Cancer 2(Suppl 3):126

    Google Scholar 

  21. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M (2001) Letrozole neo-adjuvant breast cancer study group: preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532

    Article  PubMed  CAS  Google Scholar 

  22. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M (2003) European organization for the research and treatment of cancer (EORTC)-investigational drug branch for breast cancer (IDBBC): mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398

    Article  PubMed  CAS  Google Scholar 

  23. ATAC Trialists Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after competion of 5 years‘ adjuvant treatment for breast cancer. Lancet 365:60–62

    Article  CAS  Google Scholar 

  24. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) Intergroup exemestane study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article  PubMed  CAS  Google Scholar 

  25. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

    Article  PubMed  CAS  Google Scholar 

  26. Howell A, Robertson J, Quaresma AJ, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progreassing after prior endocrine treatment. J Clin Oncol 20:3396–3403

    Article  PubMed  CAS  Google Scholar 

  27. Osborne C, Pippen J, Jones S, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) A double-blind, double-dummy randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progression prior on endocrine therapy: results of a north american trial. J Clin Oncol 20:3386–3395

    Article  PubMed  CAS  Google Scholar 

  28. Buzdar A (1998) The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 78:16–20

    PubMed  CAS  Google Scholar 

  29. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for an advanced breast cancer versus megestrol acetate. J Clin Oncol 14:3357–3366

    Google Scholar 

  30. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) The ATAC (Arimidex, Tamoxifen Alone or in Combination) trialists‘ group: anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

    Article  PubMed  CAS  Google Scholar 

  31. Coombes R, Hall E, Snowdon C, Bliss JM (2004) The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen – updated survival analysis. In: Abstracts of the 3rd san antonio breast cancer symposium, San Antonio, TX, 8–10 December 2004

  32. Howell The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 5 years. In: Abstracts of the 1st San Antonio breast cancer symposium, San Antonio, TX, 8–10 December 2004

  33. Fallowfield L, Price M, Hall E, Coombes R, Bliss JM (2004) Intergroup exemestane study: results of the quality of life sub-protocol. In: Abstracts of the 4th San Antonio breast cancer symposium, San antonio, TX, 8–10 December 2004

  34. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261–4271

    Article  PubMed  CAS  Google Scholar 

  35. Whelan T, Goss P, Ingle J, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. J Clin Oncol 23:6931–6940

    Article  PubMed  CAS  Google Scholar 

  36. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol) 16:485–491

    CAS  Google Scholar 

  37. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22:4951–4957

    Article  PubMed  Google Scholar 

  38. Howell A, Dowsett M (2004) Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 6:269–274

    Article  PubMed  CAS  Google Scholar 

  39. Bundred N, Howell A (2002) Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2:151–160

    Article  PubMed  CAS  Google Scholar 

  40. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG (2004) Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 150:243–255

    Article  PubMed  CAS  Google Scholar 

  41. Johnston S (2004) Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 90(Suppl 1):S15–S18

    Article  PubMed  CAS  Google Scholar 

  42. Ellis MJ (2004) Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. Ann Surg Oncol 11(Suppl 1):9S–17S

    Article  PubMed  Google Scholar 

  43. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816

    PubMed  CAS  Google Scholar 

  44. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290–297

    Article  PubMed  CAS  Google Scholar 

  45. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643–658

    Article  PubMed  CAS  Google Scholar 

  46. Baum M, Buzdar A (2003) The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am 83:973–994

    Article  PubMed  Google Scholar 

  47. Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP (2003) A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J 9:213–222

    Article  PubMed  CAS  Google Scholar 

  48. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327

    Article  PubMed  CAS  Google Scholar 

  49. Lonning P, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234–2244

    PubMed  CAS  Google Scholar 

  50. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L (2003) Trial 0020 investigators; trial 0021 investigators: postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79:207–211

    Article  PubMed  CAS  Google Scholar 

  51. Osborne CK (1993) Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47:83–89

    Article  PubMed  CAS  Google Scholar 

  52. Canney PA, Griffiths T, Latief TN, Priestman TJ (1987) Clinical significance of tamoxifen withdrawal response. Lancet 1:36

    Article  PubMed  CAS  Google Scholar 

  53. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG (2004) Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6:R246–R251

    Article  PubMed  CAS  Google Scholar 

  54. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835–4842

    Article  PubMed  CAS  Google Scholar 

  55. Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M (2004) Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 40:2742–2747

    Article  PubMed  CAS  Google Scholar 

  56. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(Pt 2):865s–870s

    PubMed  CAS  Google Scholar 

  57. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H (2003) Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 21:984–990

    Article  PubMed  CAS  Google Scholar 

  58. Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Moller KA, Andersen J, Munkholm P, Dombernowsky P, Christensen IJ (2000) Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res Treat 61:103–110

    Article  PubMed  CAS  Google Scholar 

  59. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM (1990) Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50:5851–5857

    PubMed  CAS  Google Scholar 

  60. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M (1999) Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 5:1642–1649

    PubMed  CAS  Google Scholar 

  61. Dowsett M, Cuzick J, Howell A, Jackson I (2001) ATAC trialists‘ group: pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 85:317–324

    Article  PubMed  CAS  Google Scholar 

  62. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE (1999) Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6:25–28

    Article  PubMed  CAS  Google Scholar 

  63. Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, Hortobagyi GN (2004) Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10:1943–1948

    Article  PubMed  CAS  Google Scholar 

  64. Yue W, Zhou D, Chen S, Brodie A (1994) A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54:5092–5095

    PubMed  CAS  Google Scholar 

  65. Brodie A (2003) Aromatase inhibitor development and hormone therapy: a perspective. Semin Oncol 30(Suppl 14):12–22

    Article  PubMed  CAS  Google Scholar 

  66. Brodie A, Jelovac D, Long BJ (2003) Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 9(Pt 2):455S–459S

    PubMed  CAS  Google Scholar 

  67. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O (2005) Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 11(Pt 2):884s–888s

    PubMed  CAS  Google Scholar 

  68. Brodie A, Lu Q, Liu Y, Long B (1999) Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 6:205–210

    Article  PubMed  CAS  Google Scholar 

  69. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A (1999) The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57:183–192

    Article  PubMed  CAS  Google Scholar 

  70. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM (2004) Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 96:456–465

    Article  PubMed  CAS  Google Scholar 

  71. Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM (2004) Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res 10:7375–7381

    Article  PubMed  CAS  Google Scholar 

  72. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM (2005) Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65:5439–5444

    Article  PubMed  CAS  Google Scholar 

  73. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ (1994) Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354–361

    Article  PubMed  CAS  Google Scholar 

  74. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA (1981) Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trialar. Br Med J (Clin Res Ed) 283:1432–1434

    Article  CAS  Google Scholar 

  75. Cameron DA, Winer E, Campos S, Guastalla J-P (2004) A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. J Clin Oncol 22(14S):628( Abstract)

    Google Scholar 

  76. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83:1142–1152

    Article  PubMed  CAS  Google Scholar 

  77. Rose C, Vtoraya O, Pluzanska A, Neave F, Clemens M, Chaudri-Ross HA, Wyld P, Lang R (2002) Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 21:131 (Abstract)

    Google Scholar 

  78. Bertelli G, Garrone O, Merlano M (2001) Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. J Clin Oncol 21(Suppl):60a

    Google Scholar 

  79. Long BJ, Jelovac D, Thiantanawat A, Brodie AM (2002) The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8:2378–2388

    PubMed  CAS  Google Scholar 

  80. 80.Jakesz R, Kaufmann M, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) ABCSG and the GABG: switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  CAS  Google Scholar 

  81. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  PubMed  CAS  Google Scholar 

  82. Thurlimann B (2005) BIG 1–98: a prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Program and abstracts from Primary Therapy of Early Breast Cancer 9th International Conference; St. Gallen, Switzerland, January 26–29, 2005. Abstract S4. [cited April 2005]; Available from: http://www.ibcsg.org/public/documents/pdf/meeting_05/BIG_1–98_SG_19Jan05-b_FINAL.pdf

  83. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC trialists‘ group: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years‘ adjuvant treatment for breast cancer. Lancet 365:60–62

    Article  PubMed  CAS  Google Scholar 

  84. Burstein HJ, Punglia RS (2005) Choosing the best adjuvant endocrine treatment strategy for patients with postmenopausal breast cancer: a decision analysis. In: Perry MC (ed) ASCO 2005 educational Book. ASCO, Alexandria, VA, pp40–44

  85. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ (2005) Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23:5178–5187

    Article  PubMed  Google Scholar 

  86. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D, Shepherd LE, Pater JL (2004) Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 22(July 15 Suppl):847 (Abstract)

  87. Ingle JN (2004) Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 10(Pt 2):362S–367S

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This manuscript was supported by an educational grant from Pfizer UK.

Author information

Authors and Affiliations

  1. Breast Unit, Western General Hospital, Paderewski Building, Edinburgh , EH4 2XU, UK

    William R. Miller

  2. Division of Cancer Sciences and Molecular Pathology,, Endocrine Cancer Group, Glasgow Royal Infirmary, Glasgow, UK

    John M. S. Bartlett

  3. Beatson Oncology Centre, Western Infirmary, Glasgow, UK

    Peter Canney

  4. Northern Institute for Cancer Research, Newcastle General Hospital, Newcastle upon Tyne, UK

    Mark Verrill

Authors
  1. William R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. S. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Canney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Verrill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William R. Miller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, W.R., Bartlett, J.M.S., Canney, P. et al. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 103, 149–160 (2007). https://doi.org/10.1007/s10549-006-9369-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9369-7

Keywords

Search

Navigation